Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Active, not recruiting

• Conditions: CV2 Autoimmunity
• Interventions: Other: Description of clinical, immunological and tumor features of patients harboring CV2 Abs

• Registration Number: NCT06620913
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/Collapsin response-mediator protein 5 (CRMP5)-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations, affecting both central and peripheral nervous system, and the most frequently associate tumor is small cell lung carcinoma. Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2/CRMP5 patients. Unraveling the complexities of CV2/CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis, treatment, and patients' care. Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2/CRMP5 patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-01
• Status Verified: 2024-09
• Primary Completion: 2024-09-01
• Study First Submitted: 2024-09-27
• Study First Submitted QC: 2024-09-30
• Last Update Submitted: 2024-09-30
• Study First Posted: 2024-10-01
• Last Update Posted: 2024-10-01
• Study Completion: 2026-05-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 232

Inclusion Criteria

• Patient with paraneoplastic neurological syndromes
• Patient with CV2 antibody in sera and/or CSF

Exclusion Criteria

• Patient with no data
• Patient without neurological disorder
• Patient without CV2 antibody in sera/CSF

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with CV2 Abs	Description of clinical, immunological and tumor features of patients harboring CV2 Abs	Patients harboring CV2 Abs and a paraneoplastic neurological syndromes.

Primary Outcome Measures

Name	Time	Method
Modified Rankin Scale (mRs)	At baseline, 3, 6, 12, 18 month	Application of modified rankin scale

Trial Locations

Locations (1)

Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est; 🇫🇷 Bron, France